(Q38586132)

4 September 2017

title

Type 2 diabetes and the skeleton: new insights into sweet bones (English)

1 reference

4 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26365605%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Deborah M Mitchell

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26365605%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Clifford J Rosen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26365605%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Mary L Bouxsein

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26365605%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

10 September 2015

1 reference

The Lancet: Diabetes & Endocrinology

4 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26365605%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26365605%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26365605%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

159-173

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26365605%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

cites work

Type 2 diabetes and bone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Risk of Fracture in Women with Type 2 Diabetes: the Women’s Health Initiative Observational Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Fracture risk in diabetic elderly men: the MrOS study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Diabetes and risk of hip fracture in the Singapore Chinese Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Glycated Hemoglobin Level and Risk of Hip Fracture in Older People with Type 2 Diabetes: A Competing Risk Analysis of Taiwan Diabetes Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Fracture risk in type 2 diabetes: update of a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Diabetes and risk of fracture: The Blue Mountains Eye Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Risk factors for fragility fracture in middle age. A prospective population-based study of 33,000 men and women.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Type 2 diabetes is associated with increased bone mineral density in Mexican-American women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Decreased bone mineral density at the distal radius, but not at the lumbar spine or the femoral neck, in Japanese type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Simulated increases in body fat and errors in bone mineral density measurements by DXA and QCT

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

A bone structural basis for fracture risk in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Diabetes and change in bone mineral density at the hip, calcaneus, spine, and radius in older women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Menopausal bone changes and incident fractures in diabetic women: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Diabetes and bone loss at the hip in older black and white adults

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Femoral neck bone loss predicts fracture risk independent of baseline BMD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Identification of osteopenic women at high risk of fracture: the OFELY study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Bone density screening intervals for osteoporosis: one size does not fit all.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Bone quality: where do we go from here?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Defects in cortical microarchitecture among African-American women with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

In vivo assessment of bone quality in postmenopausal women with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Advanced glycation endproducts in diabetes and diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Effects of Collagen Crosslinking on Bone Material Properties in Health and Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Advanced glycation end products and bone loss during aging.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Effects of non-enzymatic glycation on cancellous bone fragility.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Sacrificial bonds and hidden length dissipate energy as mineralized fibrils separate during bone fracture

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Etiology of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Glucose Uptake and Runx2 Synergize to Orchestrate Osteoblast Differentiation and Bone Formation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Biochemical markers of bone turnover in diabetes patients--a meta-analysis, and a methodological study on the effects of glucose on bone markers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Bone loss and bone turnover in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Circulating osteogenic precursor cells in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Circulating osteogenic cells: characterization and relationship to rates of bone loss in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

A meta-analysis of the association of fracture risk and body mass index in women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Obesity and fractures.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

The association between fracture and obesity is site-dependent: A population-based study in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

In obese postmenopausal women, bone microarchitecture and strength are not commensurate to greater body weight: the Os des Femmes de Lyon (OFELY) study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Bone structure and estimated bone strength in obese patients evaluated by high-resolution peripheral quantitative computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Relation of visceral and subcutaneous adipose tissue to bone mineral density in chinese women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Visceral adiposity is negatively associated with bone density and muscle attenuation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Determinants of bone microarchitecture and mechanical properties in obese men

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Determinants of bone mineral density in obese premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Insulin promotes growth of the cultured rat osteosarcoma cell line UMR-106-01: an osteoblast-like cell

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Insulin increases histomorphometric indices of bone formation In vivo

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Correlations between insulin sensitivity and bone mineral density in non-diabetic men.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Metabolic syndrome, aging and involvement of oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Reduced peripheral nerve function is related to lower hip BMD and calcaneal QUS in older white and black adults: the Health, Aging, and Body Composition Study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Reduction in Endogenous Insulin Secretion is a Risk Factor of Sarcopenia in Men with Type 2 Diabetes Mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Obesity and risk of hip fracture in adults: a meta-analysis of prospective cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

The insulin-sensitive glucose transporter (GLUT4) is involved in early bone growth in control and diabetic mice, but is regulated through the insulin-like growth factor I receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve ty

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Potential role of pancreatic and enteric hormones in regulating bone turnover.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Effects of glucose-dependent insulinotropic peptide on osteoclast function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Possible adverse effects of SGLT2 inhibitors on bone

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

SGLT inhibitors in management of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Islet amyloid polypeptide, islet amyloid, and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Inhibitory effect of amylin on basal and parathyroid hormone-stimulated bone resorption in cultured neonatal mouse calvaria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Amylin inhibits ovariectomy-induced bone loss in rats

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Amylin and bone metabolism in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Amylin exerts osteogenic actions with different efficacy depending on the diabetic status.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

FRAX underestimates fracture risk in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Interventions for preventing falls in older people living in the community

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

Falls as a complication of diabetes mellitus in older people

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2815%2900283-1

7 January 2021

10.1016/S2213-8587(15)00283-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26365605%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference